CTLT vs. SRPT, VTRS, UTHR, TEVA, RDY, JAZZ, LEGN, APLS, BMRN, and ASND
Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include Sarepta Therapeutics (SRPT), Viatris (VTRS), United Therapeutics (UTHR), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), Legend Biotech (LEGN), Apellis Pharmaceuticals (APLS), BioMarin Pharmaceutical (BMRN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Catalent vs.
Catalent (NYSE:CTLT) and Sarepta Therapeutics (NASDAQ:SRPT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
Catalent has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Catalent has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.
Catalent has a net margin of 8.62% compared to Sarepta Therapeutics' net margin of -75.40%. Catalent's return on equity of 11.40% beat Sarepta Therapeutics' return on equity.
Catalent currently has a consensus price target of $96.30, indicating a potential upside of 48.91%. Sarepta Therapeutics has a consensus price target of $166.41, indicating a potential upside of 22.33%. Given Catalent's higher probable upside, equities research analysts clearly believe Catalent is more favorable than Sarepta Therapeutics.
Sarepta Therapeutics received 755 more outperform votes than Catalent when rated by MarketBeat users. Likewise, 75.82% of users gave Sarepta Therapeutics an outperform vote while only 62.52% of users gave Catalent an outperform vote.
In the previous week, Catalent had 4 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 13 mentions for Catalent and 9 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.05 beat Catalent's score of 0.32 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.
99.4% of Catalent shares are held by institutional investors. Comparatively, 87.3% of Sarepta Therapeutics shares are held by institutional investors. 0.6% of Catalent shares are held by insiders. Comparatively, 6.4% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Catalent beats Sarepta Therapeutics on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalent Competitors List
